Thank you all in advance
GLP-1 receptor agonists such as semaglutide and tirzepatide have transformed weight management for millions of people, but pregnancy planning introduces important clinical questions
The market is expecting a repeat of 2022, so elevated inflation with growth just about holding on
Endocrine Effects Research has explored DSIPs ability to modulate the release of various hormones such as luteinizing hormone (LH), growth hormone (GH), and corticotropin
Ecnoglutide Join the conversation
Their concerns were categorized as follows: Overprescribing (clinically inappropriate prescribing): 56% Compromised continuity of care (e.g., follow-up visits, titration, tapering off medication): 50% Lack of complete medical history: 47% Medication interactions and/or side effect management: 43% Lack of transparency to the patients broader care team: 32% Prevalence of compounded GLP-1s/GIPs: 32% Lack of holistic support of weight management: 24% Researchers have raised marketing and safety concerns about compounded and counterfeit GLP-1s, and the FDA recommends that patients "obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy." However, patient demand for these drugs is likely to persist due to their significantly lower costs
